169 related articles for article (PubMed ID: 24823643)
21. Systemic in vivo distribution of activatable cell penetrating peptides is superior to that of cell penetrating peptides.
Aguilera TA; Olson ES; Timmers MM; Jiang T; Tsien RY
Integr Biol (Camb); 2009 Jun; 1(5-6):371-81. PubMed ID: 20023744
[TBL] [Abstract][Full Text] [Related]
22. Internalization of Near-Infrared Fluorescently Labeled Activatable Cell-Penetrating Peptide and of Proteins into Human Fibrosarcoma Cell Line HT-1080.
Tansi F; Kallweit E; Kaether C; Kappe K; Schumann C; Hilger I; Reissmann S
J Cell Biochem; 2015 Jul; 116(7):1222-31. PubMed ID: 25546737
[TBL] [Abstract][Full Text] [Related]
23. Identification of High-Risk Plaques by MRI and Fluorescence Imaging in a Rabbit Model of Atherothrombosis.
Hua N; Baik F; Pham T; Phinikaridou A; Giordano N; Friedman B; Whitney M; Nguyen QT; Tsien RY; Hamilton JA
PLoS One; 2015; 10(10):e0139833. PubMed ID: 26448434
[TBL] [Abstract][Full Text] [Related]
24. Upregulation of matrix metalloproteinases (MMPs) in breast cancer xenografts: a major induction of stromal MMP-13.
Lafleur MA; Drew AF; de Sousa EL; Blick T; Bills M; Walker EC; Williams ED; Waltham M; Thompson EW
Int J Cancer; 2005 Apr; 114(4):544-54. PubMed ID: 15551360
[TBL] [Abstract][Full Text] [Related]
25. In vitro and in vivo investigation of matrix metalloproteinase expression in metastatic tumor models.
Sprague JE; Li WP; Liang K; Achilefu S; Anderson CJ
Nucl Med Biol; 2006 Feb; 33(2):227-37. PubMed ID: 16546677
[TBL] [Abstract][Full Text] [Related]
26. PEG-co-PCL nanoparticles modified with MMP-2/9 activatable low molecular weight protamine for enhanced targeted glioblastoma therapy.
Gu G; Xia H; Hu Q; Liu Z; Jiang M; Kang T; Miao D; Tu Y; Pang Z; Song Q; Yao L; Chen H; Gao X; Chen J
Biomaterials; 2013 Jan; 34(1):196-208. PubMed ID: 23069707
[TBL] [Abstract][Full Text] [Related]
27. Tissue distribution of major matrix metalloproteinases and their transcripts in human breast carcinomas.
Lebeau A; Nerlich AG; Sauer U; Lichtinghagen R; Löhrs U
Anticancer Res; 1999; 19(5B):4257-64. PubMed ID: 10628384
[TBL] [Abstract][Full Text] [Related]
28. Cell-Permeable, MMP-2 Activatable, Nickel Ferrite and His-Tagged Fusion Protein Self-Assembled Fluorescent Nanoprobe for Tumor Magnetic-Targeting and Imaging.
Sun L; Xie S; Qi J; Liu E; Liu D; Liu Q; Chen S; He H; Yang VC
ACS Appl Mater Interfaces; 2017 Nov; 9(45):39209-39222. PubMed ID: 29058417
[TBL] [Abstract][Full Text] [Related]
29. Angiopep-2 and activatable cell-penetrating peptide dual-functionalized nanoparticles for systemic glioma-targeting delivery.
Gao H; Zhang S; Cao S; Yang Z; Pang Z; Jiang X
Mol Pharm; 2014 Aug; 11(8):2755-63. PubMed ID: 24983928
[TBL] [Abstract][Full Text] [Related]
30. Hydrolysis Mechanism of the Linkers by Matrix Metalloproteinase-9 Using QM/MM Calculations.
Chen B; Kang Z; Zheng E; Liu Y; Gauld JW; Wang Q
J Chem Inf Model; 2021 Oct; 61(10):5203-5211. PubMed ID: 34649435
[TBL] [Abstract][Full Text] [Related]
31. Targeting MMP-14 for dual PET and fluorescence imaging of glioma in preclinical models.
Kasten BB; Jiang K; Cole D; Jani A; Udayakumar N; Gillespie GY; Lu G; Dai T; Rosenthal EL; Markert JM; Rao J; Warram JM
Eur J Nucl Med Mol Imaging; 2020 Jun; 47(6):1412-1426. PubMed ID: 31773232
[TBL] [Abstract][Full Text] [Related]
32. Noninvasive visualization of tumoral fibrin deposition using a peptidic fibrin-binding single photon emission computed tomography tracer.
Starmans LW; van Mourik T; Rossin R; Verel I; Nicolay K; Grüll H
Mol Pharm; 2015 Jun; 12(6):1921-8. PubMed ID: 25922977
[TBL] [Abstract][Full Text] [Related]
33. Angiopep-2 and activatable cell penetrating peptide dual modified nanoparticles for enhanced tumor targeting and penetrating.
Mei L; Zhang Q; Yang Y; He Q; Gao H
Int J Pharm; 2014 Oct; 474(1-2):95-102. PubMed ID: 25138251
[TBL] [Abstract][Full Text] [Related]
34. Expression of matrix metalloproteinases in the microenvironment of spontaneous and experimental melanoma metastases reflects the requirements for tumor formation.
Hofmann UB; Eggert AA; Blass K; Bröcker EB; Becker JC
Cancer Res; 2003 Dec; 63(23):8221-5. PubMed ID: 14678978
[TBL] [Abstract][Full Text] [Related]
35. Impact of MMP-2 and MMP-9 enzyme activity on wound healing, tumor growth and RACPP cleavage.
Hingorani DV; Lippert CN; Crisp JL; Savariar EN; Hasselmann JPC; Kuo C; Nguyen QT; Tsien RY; Whitney MA; Ellies LG
PLoS One; 2018; 13(9):e0198464. PubMed ID: 30248101
[TBL] [Abstract][Full Text] [Related]
36. Extracellular matrix metalloproteinase inducer stimulates tumor angiogenesis by elevating vascular endothelial cell growth factor and matrix metalloproteinases.
Tang Y; Nakada MT; Kesavan P; McCabe F; Millar H; Rafferty P; Bugelski P; Yan L
Cancer Res; 2005 Apr; 65(8):3193-9. PubMed ID: 15833850
[TBL] [Abstract][Full Text] [Related]
37. A novel matrix metalloproteinase inhibitor, FYK-1388 suppresses tumor growth, metastasis and angiogenesis by human fibrosarcoma cell line.
Shinoda K; Shibuya M; Hibino S; Ono Y; Matsuda K; Takemura A; Zou D; Kokubo Y; Takechi A; Kudoh S
Int J Oncol; 2003 Feb; 22(2):281-8. PubMed ID: 12527923
[TBL] [Abstract][Full Text] [Related]
38. Radionuclide imaging of tumor xenografts in mice using a gelatinase-targeting peptide.
Medina OP; Kairemo K; Valtanen H; Kangasniemi A; Kaukinen S; Ahonen I; Permi P; Annila A; Sneck M; Holopainen JM; Karonen SL; Kinnunen PK; Koivunen E
Anticancer Res; 2005; 25(1A):33-42. PubMed ID: 15816516
[TBL] [Abstract][Full Text] [Related]
39. Targeting of gelatinase activity with a radiolabeled cyclic HWGF peptide.
Kuhnast B; Bodenstein C; Haubner R; Wester HJ; Senekowitsch-Schmidtke R; Schwaiger M; Weber WA
Nucl Med Biol; 2004 Apr; 31(3):337-44. PubMed ID: 15028246
[TBL] [Abstract][Full Text] [Related]
40. Development of a Radiolabeled Peptide-Based Probe Targeting MT1-MMP for Breast Cancer Detection.
Min K; Ji B; Zhao M; Ji T; Chen B; Fang X; Ma Q
PLoS One; 2015; 10(10):e0139471. PubMed ID: 26437463
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
